Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
Go back to Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology| (NYSE: ATH) | Delayed: 83.33 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $83.33 | 52 Week High | $ | |||
| Open | $83.33 | 52 Week Low | $ | |||
| Day High | $83.33 | P/E | N/A | |||
| Day Low | $83.33 | EPS | $ | |||
| Volume | 7,858 | |||||
| (NASDAQ: ATHE) | Delayed: 4.93 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.93 | 52 Week High | $ | |||
| Open | $4.93 | 52 Week Low | $ | |||
| Day High | $4.93 | P/E | N/A | |||
| Day Low | $4.93 | EPS | $ | |||
| Volume | 56 | |||||
